prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a german observational study在精神分裂症患者代谢综合征患病率,代谢变化与抗精神病药物治疗3个月后u2014u2014德国观察研究的结果.pdfVIP

Kraemer et al. BMC Psychiatry 2011, 11:173 /1471-244X/11/173 RESEARCH ARTICLE Open Access Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study 1* 1 2 3 1 Susanne Kraemer , Anette Minarzyk , Thomas Forst , Daniel Kopf and Hans-Peter Hundemer Abstract Background: This observational study explored the prevalence of metabolic syndrome (MetS) in adult in- and outpatients with untreated or treated schizophrenia at baseline, and month-3 after initiation or switch of antipsychotic treatment. Methods: MetS-prevalence (AHA/NHLB-definition) was assessed and Clopper-Pearson 95% confidence intervals (CIs) were calculated. Factors associated with MetS were explored through univariate and multivariate logistic regressions (both visits). Results: MetS-prevalence was 44.3% (CI 39.8;48.9) at baseline and 49.6% (CI 45.0;54.2) at month-3. Previously unmedicated patients showed the lowest baseline MetS-prevalence (24.7%, CI 18.3;32.1). MetS-prevalence was not significantly different, regardless if patients previously received typical or atypical antipsychotics. Increased MetS-risk was associated with somatic comorbidity and non-smoking at both visits, and with non-psychiatric co-medication, male sex, and increased C-reactive protein at month-3. Conclusions: At baseline, MetS was most prevalent in patients with previous antipsychotic medication. Limited metabolic changes were observed 3 months after switch/initiation of antipsychotic therapy. Trial Registration Number: ClinicalT Identifier: n.a. Background abdominal fat (IAF) in